- Home
- ARCT vs PCRX Comparison
ARCT vs PCRX Comparison
Compare ARCT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- PCRX
- Stock Information
- Founded
- ARCT 2013
- PCRX 2006
- Country
- ARCT United States
- PCRX United States
- Employees
- ARCT N/A
- PCRX N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- PCRX Health Care
- Exchange
- ARCT Nasdaq
- PCRX Nasdaq
- Market Cap
- ARCT 487.0M
- PCRX 1.2B
- IPO Year
- ARCT N/A
- PCRX 2011
- Fundamental
- Price
- ARCT $16.36
- PCRX $26.09
- Analyst Decision
- ARCT Strong Buy
- PCRX Buy
- Analyst Count
- ARCT 8
- PCRX 10
- Target Price
- ARCT $61.00
- PCRX $29.30
- AVG Volume (30 Days)
- ARCT 405.9K
- PCRX 892.8K
- Earning Date
- ARCT 03-06-2025
- PCRX 02-27-2025
- Dividend Yield
- ARCT N/A
- PCRX N/A
- EPS Growth
- ARCT N/A
- PCRX N/A
- EPS
- ARCT N/A
- PCRX N/A
- Revenue
- ARCT $160,399,000.00
- PCRX $694,957,000.00
- Revenue This Year
- ARCT $7.33
- PCRX $5.14
- Revenue Next Year
- ARCT $4.71
- PCRX $2.44
- P/E Ratio
- ARCT N/A
- PCRX N/A
- Revenue Growth
- ARCT N/A
- PCRX 4.40
- 52 Week Low
- ARCT $14.30
- PCRX $11.16
- 52 Week High
- ARCT $45.00
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- ARCT 45.85
- PCRX 77.75
- Support Level
- ARCT $15.34
- PCRX $25.06
- Resistance Level
- ARCT $17.95
- PCRX $27.10
- Average True Range (ATR)
- ARCT 1.17
- PCRX 1.45
- MACD
- ARCT -0.08
- PCRX 0.28
- Stochastic Oscillator
- ARCT 39.08
- PCRX 86.23
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.